Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Training on PD-L1 scoring in non-small cell lung cancer with high intra- and inter-reader agreement: results of a worldwide microscopic/digital image-based training of 751 pathologists.

British journal of biomedical science·2026
Same author

HER2 testing in multiple solid tumor types: concordance of immunohistochemistry scores between three HER2 scoring algorithms.

Virchows Archiv : an international journal of pathology·2026
Same author

Filling in the Gaps of Examining Human Epidermal Growth Factor Receptor 2 (HER2)-Low and HER2-Ultralow in Breast Cancer: Clone Choice, Sample Size, and Reevaluating Scores Made on Archived Samples.

Archives of pathology & laboratory medicine·2026
Same author

New standards in HER2-low testing: the CASI-01 comparative methods study.

EBioMedicine·2025
Same author

Claudin-18.2 immunohistochemical evaluation in pancreatic cancer specimens: review and recommendations for routine testing and scoring.

Virchows Archiv : an international journal of pathology·2025
Same author

A Global Ring Study: Concordance Between Ventana PATHWAY Anti-HER2/neu (4B5) Companion Diagnostic Assay and Comparators in Detecting HER2-Low Breast Cancer.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2025
Same journal

[Connective (tissue) pathology: What brings us together!]

Der Pathologe·2022
Same journal

[Giant cell-containing tumors of bone and differential diagnoses].

Der Pathologe·2022
Same journal

[Automation and application of robotics in the pathology laboratory].

Der Pathologe·2022
Same journal

[Practical diagnostic aspects of uterine leiomyosarcoma in the context of the 2020 WHO classification].

Der Pathologe·2022
Same journal

[Artificial intelligence: a solution for the lack of pathologists?]

Der Pathologe·2022
Same journal

[Predictive immunocytochemistry in non-small cell lung carcinoma].

Der Pathologe·2022
See all related articles

Related Experiment Video

Updated: Nov 24, 2025

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.9K

ISH-based HER2 diagnostics.

Josef Rüschoff1,2, Iris Nagelmeier3, Bharat Jasani4

  • 1Institute of Pathology Nordhessen, Germaniastr. 7, 34119, Kassel, Germany. rueschoff@patho-nordhessen.de.

Der Pathologe
|December 21, 2020
PubMed
Summary
This summary is machine-generated.

Testing for HER2 alterations is crucial for targeted therapies. New methods like next-generation sequencing detect HER2 mutations and amplification, expanding treatment options for various cancers.

Keywords:
HER2 diagnosticsImmunohistochemistryNext generation sequencingTesting guidelinesin situ hybridization

More Related Videos

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

468
Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation
10:21

Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation

Published on: December 25, 2017

14.0K

Related Experiment Videos

Last Updated: Nov 24, 2025

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.9K
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

468
Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation
10:21

Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation

Published on: December 25, 2017

14.0K

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Genetics

Background:

  • HER2 testing (overexpression/amplification) is essential for HER2-directed therapies in breast and gastric cancers.
  • ASCO/CAP guidelines have evolved, with the 2018 breast cancer guidelines addressing ISH issues and 2017 gastroesophageal guidelines extending to other cancers.
  • HER2 gene mutations are emerging as a significant factor alongside overexpression and amplification.

Purpose of the Study:

  • To review the evolution and current status of HER2 testing guidelines.
  • To highlight the increasing importance of detecting HER2 gene mutations.
  • To discuss the role of next-generation sequencing in HER2 analysis.

Main Methods:

  • Review of ASCO/CAP guidelines for HER2 testing in various cancers.
  • Analysis of recent research on HER2 gene alterations, including mutations.
  • Discussion of next-generation sequencing (NGS) capabilities for HER2 detection.

Main Results:

  • Established guidelines exist for HER2 testing in breast and gastroesophageal cancers, with adaptations for other tumor types.
  • HER2 gene mutations are increasingly recognized as clinically relevant.
  • NGS enables simultaneous detection of HER2 amplification and mutations.

Conclusions:

  • Accurate HER2 testing is fundamental for guiding targeted cancer therapy.
  • The detection of HER2 mutations via NGS opens new therapeutic avenues.
  • Evolving diagnostic approaches are critical for personalized oncology.